Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US11020390B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 15, 2018 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | May 22, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/096
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.